Predicting Mortality of Incident Dialysis Patients in Taiwan - A Longitudinal Population-Based Study

Ping-Hsun Wu1,4, Yi-Ting Lin2,3, Tzu-Chi Lee2, Ming-Yen Lin1, Mei-Chuan Kuo1,5*, Yi-Wen Chiu1,5, Shang-Yjh Hwang1,5, Hung-Chun Chen1,5

1 Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 2 Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 3 Department of Public Health, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 4 Department of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 5 Faculty of Renal Care, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

Abstract

Background: Comorbid conditions are highly prevalent among patients with end-stage renal disease (ESRD) and index score is a predictor of mortality in dialysis patients. The aim of this study is to perform a population-based cohort study to investigate the survival rate by age and Charlson comorbidity index (CCI) in incident dialysis patients.

Methods: Using the catastrophic illness registration of the Taiwan National Health Insurance Research Database for all patients from 1 January 1998 to 31 December 2008, individuals newly diagnosed with ESRD and receiving dialysis for more than 90 days were eligible for our study. Individuals younger than 18 years or renal transplantation patients either before or after dialysis were excluded. We calculated the CCI, age-weighted CCI by Deyo-Charlson method according to ICD-9 code and categorized CCI into six groups as index scores ≤3, 4–6, 7–9, 10–12, 13–15, >15. Cox regression models were used to analyze the association between age, CCI and survival, and the risk markers of survival.

Results: There were 79,645 incident dialysis patients, whose mean age (± SD) was 60.96 (±13.92) years; 51.43% of patients were women and 51.2% were diabetic. In cox proportional hazard models and stratifying by age, older patients had significantly higher mortality than younger patients. The mortality risk was higher in persons with higher CCI as compared with low CCI. Mortality increased steadily with higher age or comorbidity both for unadjusted and for adjusted models. For all age groups, mortality rates increased in different CCI groups with the highest rates occurring in the oldest age groups.

Conclusions: Age and CCI are both strong predictors of survival in Taiwan. The older age or higher comorbidity index in incident dialysis patient is associated with lower long-term survival rates. These population-based estimates may assist clinicians who make decisions when patients need long-term dialysis.

Introduction

End-stage renal disease (ESRD) patients have a high prevalence of comorbid conditions [1,2], high mortality rate [3–5], and poor prognosis. Although the prognosis for patients with ESRD treated by dialysis has improved in recent years, mortality rates remain high. The ESRD population is high in Taiwan and patients start dialysis with very low residual renal function and in poor clinical conditions [6]. Compared with populations in western countries, cardiovascular disease occurs less frequently among Asians [7] and late dialysis in Taiwan with low mortality [6] is quite different from other countries. Besides, there is no difference in survival rates between hemodialysis and peritoneal dialysis patients in Taiwan [8,9]. The median serum creatinine and glomerular filtration rate (GFR) are 10.1 mg/dL and 4.7 mL/min/1.73m² in Taiwan and lower GFR at dialysis initiation is associated with lower mortality [10]. This finding is similar to the result in an IDEAL (Initiating Dialysis Early and Late) study that mentioned early initiation of dialysis principle was not associated with an improvement in survival or clinical outcomes [11]. Although late dialysis strategy is applied in Taiwan, comorbidity is still a major confounder but also a predictor of the patient’s natural course and outcomes. Therefore, comorbidity should be assessed in dialysis patients and simplified comorbidity indexes are more applicable. Comorbidity scales have been evaluated in dialysis patients, such as Charlson comorbidity index (CCI) [12], index of co-existent diseases (ICED) [13], Davies [14], and Wright-Khan indices [3]. Of the comorbidity scales developed for general medical patients, CCI is the most popular [12] and easiest to apply. CCI was originally developed to create a single-value summary for several comorbid conditions for breast cancer patients in 1984 and is suitable for general medical inpatient populations. It is also applied to the dialysis population.
and also validated in ESRD patients [5,15]. ICED works better than CCI in analyses of ESRD patients but ICED is difficult to apply [13]. CCI is also a better predictor for mortality compared with the Davies comorbidity index for peritoneal dialysis patients [16]. However, previous studies examining on incident dialysis populations were performed in single centers, involved small numbers of patients, and had short-term duration. Few reports predict long-term mortality in dialysis patients [17,18] and publications on this subject in Asian populations are rare [19]. Age with CCI as a good predictor of long term prognosis in dialysis patients in Taiwan is still unknown. The objective of the present study is to predict long term survival in large sample incident dialysis patients using CCI and age-weight CCI in a 10-year nationwide cohort study. We used claims data from the National Health Insurance program in Taiwan to evaluate the comorbidities during pre-dialysis care and to investigate the relationship between CCI and survival in incident patients. Population-based data often contains all patients with a given disease, and administrative data offer a picture of the “real world” effectiveness of interventions as they are being practiced.

Methods

Data Source

This study is based on a longitudinal health insurance database, the National Health Insurance Research Database (NHIRD), provided by the Taiwan National Health Research Institute. Taiwan launched its compulsory social insurance program, National Health Insurance (NHI), to provide health care for all the island’s residents since 1995. The annual coverage rate of the NHI program ranged from 96.16% to 99.6% and includes contracts with 97% of hospitals and clinics, with more than 23 million Taiwanese residents enrolled since 1997. It covers all medical benefit claims of ambulant and inpatient care and is extensively applied to many epidemiological studies. The NHIRD established a registry system for “Catastrophic Illnesses”, including cancer, chronic mental illness, end-stage renal disease, congenital illness, and several autoimmune diseases. Insured persons with major diseases can apply for catastrophic illness registration cards from the Bureau of National Health Insurance (BNHI) and do not need to make co-payments when seeking health care for catastrophic illness. Both outpatient and inpatient claims of beneficiaries with a catastrophic illness certificate are collected in the catastrophic illness profile and are distributed as a package. The BNHI performs routine validations of the diagnoses by reviewing the original medical charts of all of the patients who apply for catastrophic illness registration. In this study, all cases of dialysis patients are obtained from the Registry of Catastrophic Illness Database, a subpart of the NHIRD. The issuance of catastrophic illness certificates is validated by at least 2 specialists, based on careful examination of the medical records, laboratory studies, imaging studies, and dialysis treatment. Only individuals who meet the diagnostic criteria for major diseases are issued a catastrophic illness certificate. The database included all relevant information about the “catastrophic illness certificate” status, such as diagnostic codes in the format of the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM), date of diagnosis, date of death, date of receiving dialysis, date of every clinic visits, details of prescriptions, expenditure amounts, and outpatient/inpatient claimed data for the beneficiaries with catastrophic illnesses during the period 1998–2008. During the study period, International Classification of Diseases, Ninth Revision (ICD-9) codes are used to define diseases. Personal information including family history, lifestyle, and habits such as smoking and alcohol use are not available from the NHIRD.

Study Cohorts

From the Registry for Catastrophic Illness Patient Database, we selected all patients diagnosed ESRD defined as those who had catastrophic illness registration cards for ESRD (ICD-9-CM code 585) and started hemodialysis or peritoneal dialysis of more than 90 days of renal replacement therapy between Jan, 1, 1998, and Dec, 31, 2008. The NHIRD are enrolled since 1997, so the study cohort started from 1998, as a wash-out period for one year, and we also extended the observation time until 2009 in this cohort study. We excluded individuals younger than 18 years (n = 377) or those who had renal transplantation either
Predict Mortality of Dialysis Patients

A

![Graph A](image)

B

![Graph B](image)
before or after dialysis (n = 1585). Patients receiving regular dialysis without catastrophic illness certificate were not included in this study.

Under the reimbursement system, hospitals have to claim medical expenses from the NHI based on the diagnosis or treatment codes for the disease presented by their patients. We used all diagnosis codes for a full year to define the existing comorbidities, including outpatient and inpatient diagnosis codes before the date of starting dialysis, which is defined as the index date. CCI and age-weighted CCI are calculated according to all diagnosis codes for a full year before the index date on every inpatient or outpatient to define the existing comorbidities [20]. Follow-up began on the index date until death or remaining alive at the end of the study period (Dec, 31, 2009). The CCI is defined by Charlson et al [12] and the Deyo-Charlson comorbidity index (table S1), based on ICD-9 codes in claims data, has been widely used in the analyses of the impact of comorbidities on mortality [21]. The CCI contains the following components: 1 point is assigned for history of myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, peptic ulcer disease, mild liver disease and diabetes without end organ damage; 2 points for hemiplegia, moderate to severe renal disease (excluded in our scale because all patients had diagnosis of ESRD) diabetes with end organ damage, tumor without metastases, leukemia, lymphoma and myeloma; 3 points for moderate or severe liver disease; and 6 points for metastatic solid tumor or full-blown acquired immunodeficiency syndrome (still included in this study’s scale because of small numbers of dialysis patients) (table S2). As for Age-weighted-CCI, 1 point is added to the score for every decade more than 40 years of age (0 points for 18–49 years, 1 point for 50–59 years, 2 points for 60–69 years, 3 points for 70–79 years, 4 points for 80–89 years, 5 points for 90–99 years) (table S3). Because all patients are on dialysis, the minimum Charlson score is 2. All dialysis patients with diabetes are defined as diabetes with end organ damage. We categorized CCI into six groups as index scores ≤3, 4–6, 7–9, 10–12, 13–15, >15. Hazard ratio of mortality in dialysis patients by six comorbidity index groups and different age groups were analyzed.

Statistical Analysis

Data is summarized using proportions, and means (±standard deviation) as appropriate. The association between CCI and mortality was assessed using Cox proportional hazards model and Kaplan–Meier estimate with log rank tests declaring survival in the follow-up period for dialysis patients for each CCI level. In the mortality analyses, the patients were followed until event (death) or censoring [lost to follow-up or end of follow-up period]; which ever happened first. The variables were analyzed initially by univariate analysis, and statistically significant variables were chosen for multivariate analysis. Analyses were performed using the SAS statistical package (version 9.2; SAS Institute Inc, www.sas.com).

Figure 2. Survival curve stratified by Charlson comorbidity index (CCI) and age-weighted CCI. (A) Kaplan-Meier curves for 10 year survival by CCI score in incident patients. (B) Kaplan-Meier curves for 10 year survival by age-weighted CCI score. Survival is calculated beginning 90 days after starting dialysis. The survival rate of incident patients declined as CCI increased. A similar phenomenon is observed in incident patients in age-weighted CCI.

doi:10.1371/journal.pone.0061930.g002

Figure 3. Increase of mortality with old age and high CCI in incident dialysis cohort. All the bars represent hazard ratio by age group and CCI.

doi:10.1371/journal.pone.0061930.g003
All statistical tests were 2 sided. \( p \)-value \(<0.05\) was considered statistically significant.

### Results

The study population in the analyses was representative of the Taiwan dialysis population and enrolled 79,645 incident patients with ESRD. Patient's clinical characteristics and comorbid conditions are listed in Table 1. The patient's mean age (\( \pm SD \)) was 60.96 (\( \pm 13.92 \)) years, 51.4\% of patients were women, 51.2\% were diabetic. After ranking subjects according to CCI scores, we categorized them into score quartiles with 10,604, 30,930, 24,993, 9,637, 2,630, 851 numbers of patients in the six groups respectively. The distribution of CCI into six groups were 13.3\% in index scores \( \leq 3 \), 38.8\% in index scores 4–6, 31.4\% in index scores 7–9, 12.1\% in index scores 10–12, 3.3\% in index scores 13–15, and 1.1\% in index scores \( \geq 15 \). We made the same categorization in age-weighted CCI into six groups as listed in Table 1. Older patients were more likely to be in the higher comorbidity index (Figure 1). In cox proportional hazard models and stratifying by age, older patients had significantly higher mortality than younger patients: at age 30 to 39 years, the adjusted hazard ratio (aHR) was 1.20 (95\% CI, 1.02–1.40), at age 40 to 49 years, the aHR was 1.74 (95\% CI, 1.51–2.01), at age 50 to 59 years, the aHR was 2.71 (95\% CI, 2.36–3.12), at age 60 to 69 years, the aHR was 4.11 (95\% CI, 3.57–4.72), at age 70 to 79 years, the aHR was 6.27 (95\% CI, 5.45–7.21), at age older than 80 years, the aHR was 10.40 (95\% CI, 9.02–12.00), respectively. For every increased age of one year, the relative risk of death was 1.050 (95\% CI 1.049–1.050, \( p \)-value <0.001) (data not shown).

Males had higher risk of all-cause mortality compared to females significantly (aHR was 1.16, \( p \)-value <0.001). For CCI scores, mortality increased steadily with higher comorbidity both for unadjusted and for adjusted models. Compared to the lowest comorbidity group [reference group], fully adjusted models of CCI 4–6, CCI 7–9, CCI 10–12, CCI 13–15, CCI \( \geq 15 \) showed hazard

| Variable                  | Crude HR | 95\% CI     | \( p \)-value | Adjust HR | 95\% CI     | \( p \)-value |
|---------------------------|----------|-------------|---------------|-----------|-------------|---------------|
| Age group, years          |          |             |               |           |             |               |
| 18–29                     | 1(Ref.)  | –           | –             | 1(Ref.)   | –           | –             |
| 30–39                     | 1.26     | 1.08–1.48   | 0.004         | 1.20      | 1.02–1.40   | 0.025         |
| 40–49                     | 2.15     | 1.87–2.49   | <0.001        | 1.74      | 1.51–2.01   | <0.001        |
| 50–59                     | 3.89     | 3.38–4.47   | <0.001        | 2.71      | 2.36–3.12   | <0.001        |
| 60–69                     | 6.05     | 5.26–6.95   | <0.001        | 4.11      | 3.57–4.72   | <0.001        |
| 70–79                     | 9.04     | 7.87–10.39  | <0.001        | 6.27      | 5.45–7.21   | <0.001        |
| \( \geq 80 \)             | 14.57    | 12.64–18.00 | <0.001        | 10.40     | 9.02–12.00  | <0.001        |
| Sex                       |          |             |               |           |             |               |
| Men                       | 1.13     | 1.11–1.16   | <0.001        | 1.13      | 1.13–1.18   | <0.001        |
| Women                     | 1(Ref.)  | –           | –             | 1(Ref.)   | –           | –             |
| CCI                       |          |             |               |           |             |               |
| \( \leq 3 \)              | 1(Ref.)  | –           | –             | 1(Ref.)   | –           | –             |
| 4–6                       | 2.49     | 2.35–2.63   | <0.001        | 1.91      | 1.81–2.02   | <0.001        |
| 7–9                       | 3.53     | 3.34–3.73   | <0.001        | 2.39      | 2.26–2.53   | <0.001        |
| 10–12                     | 3.66     | 3.45–3.88   | <0.001        | 2.42      | 2.28–2.57   | <0.001        |
| 13–15                     | 4.12     | 3.84–4.42   | <0.001        | 2.62      | 2.44–2.81   | <0.001        |
| \( \geq 15 \)             | 4.42     | 4.02–4.86   | <0.001        | 2.78      | 2.53–3.05   | <0.001        |

**Footnotes:** CCI, Charlson comorbidity index; HR, Hazard ratio. doi:10.1371/journal.pone.0061930.t002
Discussion

For all age groups, mortality rates increased in different CCI extremely higher than the CCI 10- to 12-point group (Figure 3). Among elderly patients with age more than 80 years and CCI more than 13 points, mortality rates were extremely higher than for younger patients. Among elderly patients with age more than 80 years and CCI more than 13 points, mortality rates were increasing steadily with higher age or comorbidity both for unadjusted and for adjusted models. Figure 2A shows the survival curve for CCI stratified according to six comorbidity index groups. The same survival curve is illustrated in Figure 2B as age-weighted CCI. Death rates increased both with increasing age and increasing CCI score (Figure 3). Baseline mortality rates among older patients with CCI scores 2 to 3 points were higher than for younger patients. Among elderly patients with age more than 80 years and CCI more than 13 points, mortality rates were extremely higher than the CCI 10- to 12-point group (Figure 3). For all age groups, mortality rates increased in different CCI groups with the highest rates occurring in the oldest age groups.

Conclusion

In conclusion, age and CCI, an index of overall comorbidity, assessed at the onset of dialysis, was the strong predictor of survival. Long-term survival rate was low in incident dialysis patients in the elderly and with higher comorbidity indexes. The simply CCI score should be emphasized in every incident dialysis patient to predict long term mortality and also evaluate his/her quality of life.
References

1. Bradbury BD, Fisell RB, Albert JM, Anthony MS, Critchlow CW, et al. (2007) Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2: 89–99.

2. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, et al. (2009) United States Renal Data System 2008 Annual Data Report. Am J Kidney Dis 53: S1–374.

3. Khan IH, Catto GR, Edvard N, Fleming LW, Henderson IS, et al. (1993) Influence of coexisting disease on survival on renal-replacement therapy. Lancet 341: 415–419.

4. Nicolucci A, Cubasso D, Labbrozzi D, Mari E, Impicciatore P, et al. (1992) Effect of coexistent diseases on survival of patients undergoing dialysis. ASAIO J 38: M291–295.

5. van Manen JG, Kroezaar JC, Dekker FW, Boechnotten EW, Bouvy PM, et al. (2002) How to adjust for comorbidity in survival studies in ESRD patients: a comparison of different indices. Am J Kidney Dis 40: 82–89.

6. Yang WC, Hwang SJ (2008) Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance. Nephrol Dial Transplant 23: 3977–3982.

7. Urushima H, Okayama A, Saitoh S, Nakagawa H, Rodriguez B, et al. (2003) Differences in cardiovascular disease risk factors between Japanese in Japan and Japanese-Americans in Hawaii: the INTERLIPID study. J Hum Hypertens 17: 631–639.

8. Lee CC, Sun CY, Wu MS (2009) Long-term modality-related mortality analysis in incident dialysis patients. Perit Dial Int 29: 162–190.

9. Chang YK, Hsu CC, Hwang SJ, Chen PC, Huang CC, et al. (2012) A comparative assessment of survival between propensity score-matched patients with peritoneal dialysis and hemodialysis in taiwan. Medicine (Baltimore) 91: 144–151.

10. Hwang SJ, Yang WC, Lin MY, Mau LW, Chen HC (2010) Impact of the clinical conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study in Taiwan. Nephrol Dial Transplant 25: 2616–2624.

11. Cooper BA, Braney P, Bulfone L, Collins JF, Craig JC, et al. (2010) A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 363: 699–619.

12. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373–383.

13. Athienites NV, Miskulin DC, Fernandez G, Bunnapradist S, Simon G, et al. (2000) Comorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent disease. Semin Dial 13: 320–326.

14. Davies SJ, Russell L, Bryan J, Phillips L, Russell GI (1995) Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: their interrelationship and prediction of survival. Am J Kidney Dis 26: 353–361.

15. Hall SF (2006) A user’s guide to selecting a comorbidity index for clinical research. J Clin Epidemiol 59: 849–855.

16. Fried L, Bernardo J, Piraino B (2001) Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. Am J Kidney Dis 37: 337–342.

17. Geddes CC, van Dijk PC, McArthur S, Metcalfe W, Jager KJ, et al. (2006) The ERA-EDTA cohort study–comparison of methods to predict survival on renal replacement therapy. Nephrol Dial Transplant 21: 945–956.

18. Miskulin D, Bragg-Gresham J, Gillespie BW, Tentori F, Fiovis RL, et al. (2009) Key comorbid conditions that are predictive of survival among hemodialysis patients. Clin J Am Soc Nephrol 4: 1818–1826.

19. Chae JW, Song CS, Kim H, Lee KB, Seo BS, et al. (2011) Prediction of mortality in patients undergoing maintenance hemodialysis by Charlson Comorbidity Index using ICD-10 database. Nephron Clin Pract 117: c379–384.

20. Ng YY, Hung YN, Wu SC, Ko PJ, Hwang SM (2012) Progression in comorbidity before hemodialysis initiation is a valuable predictor of survival in incident patients. Nephrol Dial Transplant.

21. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45: 613–619.

22. Miskulin DC, Martin AA, Brown R, Fink NE, Coresh J, et al. (2004) Predicting 1 year mortality in an outpatient haemodialysis population: a comparison of comorbidity instruments. Nephrol Dial Transplant 19: 413–420.

23. Hemmelgarn BR, Manns BJ, Quan H, Gali WA (2003) Adapting the Charlson Comorbidity Index for use in patients with ESRD. Am J Kidney Dis 42: 125–132.

24. Miskulin DC, Meyer KB, Martin AA, Fink NE, Coresh J, et al. (2003) Comorbidity and its change predict survival in incident dialysis patients. Am J Kidney Dis 41: 149–161.

25. Beddhu S, Burns JF, Saul M, Seddon P, Zeidel ML (2000) A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med 108: 609–613.

26. Huang CC, Cheng KF, Wu HD (2008) Survival analysis: comparing peritoneal dialysis and hemodialysis in Taiwan. Perit Dial Int 28 Suppl 3: S15–20.

27. Lee CC, Wu CJ, Chou LH, Shen SM, Chiang SF, et al. (2012) Peripheral artery disease in peritoneal dialysis and hemodialysis patients: single-center retrospective study in Taiwan. BMC Nephrol 13: 100.

28. Luo JC, Leu HB, Huang KW, Huang CC, Hou MC, et al. (2011) Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis. CMAJ 183: E1345–1351.

29. Port FK, Hulthers-Shearon TE, Wolfe RA, Bloembergen WE, Golper TA, et al. (1999) Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 33: 507–517.

30. Mazzuchi N, Carbone P, Fernandez-Can J (2000) Importance of blood pressure control in hemodialysis patient survival. Kidney Int 58: 2147–2154.

31. Kopple JD (1994) Effect of nutrition on morbidity and mortality in maintenance dialysis patients. Am J Kidney Dis 24: 1002–1009.

32. Mason JZ, Ebben J, Xia H, Collins AJ (1999) Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: 610–619.

33. Honda H, Qureshi AR, Heimburger O, Barany P, Wang K, et al. (2006) Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Clin J Am Soc Nephrol 1: 139–148.

34. Kopple JD, Zhu X, Lew NL, Lowrie EG (1999) Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int 56: 1136–1148.